Aekkachai Tuekprakhon
Overview
Explore the profile of Aekkachai Tuekprakhon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
3084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suvannaboon R, Tuekprakhon A, Pawestri A, Pongpaksupasin P, Trinavarat A, Atchaneeyasakul L
Sci Rep
. 2025 Jan;
15(1):541.
PMID: 39747991
X-linked juvenile retinoschisis (XLRS) is an inherited retinal disease caused by mutations in the RS1 gene, resulting in splitting of the retinal layers and visual disturbances. To provide insights on...
2.
Willyanto S, Alimsjah Y, Tanjaya K, Tuekprakhon A, Pawestri A
Ann Med
. 2024 May;
56(1):2349796.
PMID: 38738799
Background: Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced treatment, remains controversial due to high relapse rates and...
3.
Ragonnet-Cronin M, Nutalai R, Huo J, Dijokaite-Guraliuc A, Das R, Tuekprakhon A, et al.
Nat Commun
. 2023 Jun;
14(1):3334.
PMID: 37286554
COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal antibodies (mAbs). To minimise virus escape from neutralisation these are administered as combinations e.g. casirivimab+imdevimab or, for...
4.
Qi S, Kiratzis I, Adoni P, Tuekprakhon A, Hill H, Stamataki Z, et al.
ACS Appl Mater Interfaces
. 2023 Mar;
15(17):20638-20648.
PMID: 36988094
In the present work, we developed an effective antimicrobial surface film based on sustainable microfibrillated cellulose. The resulting porous cellulose thin film is barely noticeable to human eyes due to...
5.
Moore S, Kronsteiner B, Longet S, Adele S, Deeks A, Liu C, et al.
Med
. 2023 Mar;
4(3):191-215.e9.
PMID: 36863347
Background: Both infection and vaccination, alone or in combination, generate antibody and T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the maintenance of such responses-and hence...
6.
Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn H, Das R, et al.
Cell Rep
. 2022 Dec;
42(1):111903.
PMID: 36586406
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused successive global waves of infection. These variants, with multiple mutations in the spike protein, are thought to facilitate escape...
7.
Suvannaboon R, Pawestri A, Jinda W, Tuekprakhon A, Trinavarat A, Atchaneeyasakul L
Sci Rep
. 2022 Dec;
12(1):21494.
PMID: 36513702
Retinitis pigmentosa (RP) affects 1:5000 individuals worldwide. Interestingly, variations in 271 RP-related genes are indicated to vary among populations. We aimed to evaluate the genetic prevalence and phenotypic profiles of...
8.
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn H, Selvaraj M, et al.
Cell
. 2022 Jun;
185(14):2422-2433.e13.
PMID: 35772405
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial...
9.
Nutalai R, Zhou D, Tuekprakhon A, Ginn H, Supasa P, Liu C, et al.
Cell
. 2022 Jun;
185(12):2116-2131.e18.
PMID: 35662412
Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1, and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA.1 and slightly...
10.
Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, et al.
Cell
. 2022 Jan;
185(3):467-484.e15.
PMID: 35081335
On 24 November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron...